Pro104 Antibody Compositions and Methods of Use

Abstract

The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.

1 . An isolated antibody which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-5277, 6076, 6077 and 6078 or competes for binding to the same epitope as the epitope bound by a monoclonal antibody produced by a hybridoma selected from the group consisting of ATCC accession number PTA-5277, 6076, 6077 and 6078. 
     
     
         2 . The antibody of  claim 1  wherein said antibody is a human antibody. 
     
     
         3 . The antibody of  claim 1  which binds to Pro104 on a mammalian cell. 
     
     
         4 . The antibody of  claim 3  which internalizes upon binding to Pro104 on a mammalian cell. 
     
     
         5 . The antibody of  claim 1  which is conjugated to a growth inhibitory agent or a cytotoxic agent. 
     
     
         6 . The antibody of  claim 1  wherein said antibody inhibits the growth of Pro104-expressing cells. 
     
     
         7 . An isolated cell that produces the antibody of  claim 1 . 
     
     
         8 . A method of killing a Pro104-expressing cell, comprising contacting the cell with the antibody of  claim 1 . 
     
     
         9 . The method of  claim 8 , wherein the antibody is a human antibody. 
     
     
         10 . The method of  claim 8 , wherein the antibody is conjugated to a cytotoxic agent. 
     
     
         11 . The method of  claim 8 , wherein the antibody is administered in conjunction with at least one chemotherapeutic agent. 
     
     
         12 . A method for detecting Pro104 overexpression in a subject in need thereof comprising comparing the level of Pro104 in a sample, determined by the binding of a Pro104 antibody of  claim 1 , from said subject to the level of Pro104 in a control, wherein an increase in the level of Pro104 in the sample from the subject as compared to the control is indicative of Pro104 overexpression in the subject. 
     
     
         13 . The antibody of  claim 1  which is detectably labeled. 
     
     
         14 . A method of imaging Pro104-expressing cells in a subject comprising detecting the presence of the antibody of  claim 13  which has been administered to said subject. 
     
     
         15 . An article of manufacture comprising a container and the antibody of  claim 1 . 
     
     
         16 . The article of manufacture of  claim 15  which further comprises a carrier. 
     
     
         17 . The article of manufacture of  claim 15  which further comprises a label or package insert. 
     
     
         18 . An isolated Pro104 specific siRNA which knocks-down Pro104 mRNA. 
     
     
         19 . The Pro104 specific siRNA of  claim 18  which down regulates Pro104 protein expression. 
     
     
         20 . The Pro104 specific siRNA of  claim 18  which induces apoptosis.